Citations

Clear

154 citation(s) found for "Levin, G".

Renal Function Decline After Vascularized Composite Allotransplantation
Ouellet, Gabriel , Sardu, Claudia , Kanitakis, Jean , Amer, Hatem, Azari, Kodi , Badet, Lionel , Brandacher, Gerald , Cendales, Linda, Özkan, Özlenen , Gaillard, Christophe , Gazarian, Aram, Kaufman, Christina , Landín, Luis , Lanzetta, Marco , Levin, L. Scott , Sassu, Paolo , Satbhai, Nilesh, Morélon, Emmanuel , Dogan, Ozlenen , Kaminska, Dorota , Lanzetta, Marco , Levin, Scott , Morales, Martin Iglesias , Sassu, Paolo , Talbot, Simon , Weissenbacher, Annemarie , Thaunat, Olivier , Morelon, Emmanuel , Petruzzo, Palmina , Amer, Hatem , Badet, L. , Cendales, Linda C. , Kamińska, Dorota , Lassus, Patrik , Iglesias, Martín , Weißenbacher, Annemarie , Thaunat, Olivier

Mayo Clinic

Transplantation Direct | July 6, 2026 | Volume: 12 | Issue: 8 | Pages: e1976

10.1097/txd.0000000000001976 | PMID 42416359 Get It

Background. Chronic kidney disease (CKD) is a common complication of nonrenal transplantation, influencing recipients’ morbidity and mortality. The incidence of CKD varies depending on the transplanted organ. Recipients of vascularized composite allotransplantation (VCA) need lifelong immunosuppression similar to that of solid organ transplantation. This study investigated renal function in VCA recipients. Methods. We studied 70 recipients from 17 centers (median follow-up: 8 y): 59 upper extremity, 10 face, and 1 penis transplant. Pretransplant and posttransplant clinical data and sera were collected to calculate the estimated glomerular filtration rate (eGFR) using the CKD Epidemiology collaboration 2021 formula. Results. Pretransplantation, the median eGFR was 105.36 mL/min (range, 71.39–155.39 mL/min). By 3 mo posttransplant, the eGFR had significantly decreased to 78.42 mL/min (range, 32.49–130.74 mL/min; P = 0.001) before stabilizing. Despite higher tacrolimus levels at 3 mo, no correlation with eGFR was found. During follow-up, 17.1% of patients experienced a ≥50% eGFR decline, 10.9% progressed to CKD, and 4.7% developed end-stage kidney disease. Some risk factors were identified, but their responsibility could not be established with certainty because of the low number of severe renal outcomes. Conclusions. Renal function declines in the majority of VCA recipients, but the function loss is lower compared with nonrenal solid organ transplantation recipients. Although no statistically significant correlation could be established between tacrolimus exposure and renal function decline, strategies aiming at minimizing calcineurin inhibitor exposure and avoiding other nephrotoxic causes are recommended to preserve long-term kidney function.
Stratified cohorts for biomarker assessment and trial readiness: TMEM175 , SCARB2 and CTSB in Parkinson’s disease
Sun, Wenhua, Wurster, Isabel, Kemmner, Roswitha, Mielke, Michele, Zetterberg, Henrik, Hauser, Ann‐Kathrin , Schulte, Claudia, Petzold, Gabor C., Spottke, Annika, Wuellner, Ullrich, Riesen, Christoph van , Mathias, Baehr, Zerr, Inga , Duezel, Emrah, Wolff, Andreas, Levin, Johannes, Hermann, Wiebke , Loehle, Mathias, Gan-Or, Ziv, Brockmann, Kathrin, Gasser, Thomas, Wurster, Isabel , Röeben, Benjamin , Zetterberg, Henrik , Lerche, Stefanie , Schulte, Claudia , Parchi, Piero , Petzold, Gabor C. , Spottke, Annika , Maass, Fabian , Falkenburger, Björn H. , Bähr, Mathias , Lingor, Paul , Xiong, Chengjie , Gan‐Or, Ziv , Brockmann, Kathrin

Mayo Clinic

No container title available | June 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.23.26356322 Get It

Abstract Background Lysosomal dysfunction plays a crucial role in the pathogenesis of Parkinson’s disease (PD), particularly among GBA1 mutation carriers. Beyond GBA1 , genes such as TMEM175 , SCARB2 , and CTSB identified in genome-wide association studies (GWAS) are also implicated in lysosomal pathways contributing to PD risk, although their functional effects in patients remain unclear. Proteins encoded by these lysosome-related genes have been explored as potential therapeutic targets in experimental models. Biomarker profiles, including clinical measures, α-syn seeding activity, lysosomal proteins, and sphingolipids, may facilitate patient stratification and support therapeutic monitoring in future clinical trials. Aim The aim of this study is to investigate the impact of genetic variants of three lysosomal-related genes ( TMEM175 , SCARB2 , and CTSB ) on biomarker profiles in PD with and without GBA1 variants. Cross-sectional data from two German cohorts: the Tuebingen Parkinson Cohort (TUEPAC) and the DESCRIBE PD cohort of the German Center for Neurodegenerative Diseases were used as explorative cohorts, and data from Accelerating Medicines Partnership® Parkinson’s Disease (AMP-PD) were used as a validation cohort. The ultimate goal is to provide new data for patient stratification based on genetics, which might serve as a readout for target engagement and treatment efficiency assessment. Methods Three cohorts were analyzed: TUEPAC, DESCRIBE PD, and AMP-PD. TUEPAC and DESCRIBE PD were combined into a single German discovery cohort (TUEPAC-DESCRIBE-PD), while AMP-PD served as an independent validation cohort. Within each cohort, for subgroup analyses, PD patients were classified as the overall PD cohort (PD all ), and further stratified by GBA1 mutation status into PD patients without GBA1 mutations (PD GBA1 _wildtype ), and PD patients carrying GBA1 mutations (PD GBA1 ). We evaluated cognitive and motor function, as well as depression using the Montreal Cognitive Assessment (MoCA), Unified Parkinson Disease Rating Scale-part I II (UPDRS III), and Beck Depression Inventory-II(BDI-II) scales. Analyzed biomarkers included CSF α-syn seeding activity using seed amplification assay (SAA), CSF lysosomal protein levels of lysosomal integral membrane protein 2 (LIMP2), also known as SCARB2, cathepsin B (CTSB) and lysosome-associated membrane protein 2 (LAMP2), blood-based enzyme activity of the lysosomal glucocerebrosidase (GCase), and CSF sphingolipid profiles. PD patients carrying risk alleles in TMEM175 , SCARB2 , and CTSB were compared to non-carriers. Results Genotype-phenotype correlation analysis in TUEPAC-DESCRIBE-PD and AMP-PD revealed: (1) In PD all , the TMEM175 p.M393T risk variant was nominally associated with decreased cognitive function when adjusted for GBA1 mutation status in TUEPAC-DESCRIBE-PD; this association could not be replicated, although a similar trend was observed in the slightly smaller, but multicentric AMP-PD cohort; TMEM175 p.M393T was not significantly associated with BDI-I I or UPDRS-III scores in either cohort. (2) In PD GBA1 _wildtype , GCase activity was significantly lower in PD patients with SCARB2 rs6812193 risk allele in TUEPAC-DESCRIBE-PD, while a similar but non-significant trend was observed in AMP-PD; (3) In PD all , CSF levels of CTSB were nominally lower in carriers of CTSB rs1293298 risk allele compared to carriers of CTSB rs1293298 protective allele in TUEPAC-DESCRIBE-PD; in PD GBA1 _wildtype , LAMP2 was significantly lower in carriers of CTSB rs1293298 risk allele compared to carriers of CTSB rs1293298 protective allele in TUEPAC-DESCRIBE-PD; (4) In PD all , TMEM175 p.M393T risk allele was nominally associated with altered sphingolipid profiles across both TUEPAC-DESCRIBE-PD and AMP-PD cohorts. Conclusion These findings demonstrate that genetic variants in lysosomal-related genes ( TMEM175 , SCARB2 , and CTSB ) have a functional impact on biomarker profiles in PD patients. Integrating genetic characterization with biochemical profiling provides a framework for patient stratification and may serve as a translational strategy to monitor target engagement and evaluate treatment efficacy in future clinical trials.
Abnormalities in core AD biomarkers precede inflammatory and glial markers in CSF in Autosomal Dominant Alzheimer’s Disease
Lin, Wenjing , Beric, Aleksandra , Baker, Bryce, Jerome, Gina, Minton, Matthew, Preminger, Sam Rose, Stauber, Jennifer, Schindler, Suzanne E, Dage, Jeff L., Aguillon, David, Benzinger, Tammie L.S., Chhatwal, Jasmeer, Daniels, Alisha , Day, Gregory, Devenney, Emma , Fox, Nick, Goate, Alison, Gordon, Brian A., Barthélemy, Nicolas R., Hassenstab, Jason, Huey, Edward D. , Jayadev, Suman, Ishiguro, Takanobu , Lee, Jae-Hong, Levey, Allan I., Levin, Johannes, Morris, John C, Perrin, Richard J., Renton, Alan E., Xiong, Chengjie, Ances, Beau M., McDade, Eric, Network, Dominantly Inherited Alzheimer, Dage, Jeffrey L. , Wisch, Julie K , Dage, Jeffrey L , Allegri, Ricardo , Aguillon, David , Benzinger, Tammie L S , Chhatwal, Jasmeer , Daniels, Alisha , Day, Gregory S , Goate, Alison M , Gordon, Brian A , Huey, Edward D , Ikeuchi, T , Jucker, Mathias , Ishiguro, Takanobu , Roh, Jee Hoon , Bateman, Randall J , Cruchaga, Carlos , Karch, Celeste M , Supnet-Bell, Charlene , Llibre-Guerra, Jorge J , Ibanez, Laura , Wisch, Julie K. , Baker, Bryce, Schindler, Suzanne E. , Allegri, Ricardo , Benzinger, Tammie L.S. , Chhatwal, Jasmeer P. , Day, Gregory S. , Fox, Nick C. , Goate, Alison , Gordon, Brian A. , Barthélemy, Nicolas R. , Hassenstab, Jason , Ikeuchi, Takeshi , Jayadev, Suman , Levey, Allan I. , Xiong, Chengjie , Morris, John C. , Perrin, Richard J. , Renton, Alan , Roh, Jee Hoon , Xiong, Chengjie , Bateman, Randall J. , Ances, Beau M. , Karch, Celeste M. , Supnet, Charlene , Llibre‐Guerra, Jorge J. , McDade, Eric , Network, Dominantly Inherited Alzheimer

Mayo Clinic

No container title available | April 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.31.26349851 | PMID 41959774 Get It

ABSTRACT BACKGROUND Increasing evidence suggests that accurate prediction of Alzheimer’s disease (AD) symptom onset requires more than amyloid- and tau-centric biomarkers such as cerebrospinal fluid (CSF) Aβ42/40, total tau and p-tau181 and plasma p-tau217. Autosomal dominant AD (ADAD), caused by pathogenic PSEN1, PSEN2 and APP mutations with predictable age at symptom onset, presents a unique opportunity to characterize the chronological changes in proteins beyond amyloid and tau and clarify them as early biomarkers of disease onset or as biomarkers related to disease staging and progression monitoring. METHODS We measured 972 CSF samples corresponding to 484 participants of the Dominantly Inherited Alzheimer Disease Network (DIAN) using the NULISASeq 120 CNS Disease Panel. We first benchmarked the technology against gold-standard measurements followed by the identification of proteins that were differentially abundant in relation to mutation status and symptomatology. Next, we determined the chronological emergence of protein changes in relation to the estimated years to onset (EYO). Finally, we assessed whether specific protein measures improved the prediction of EYO in the ADAD. FINDINGS NULISA measurements were comparable to those previously published. We demonstrated that known early alterations in CSF amyloid and tau were followed by inflammatory and neurodegenerative responses suggesting that clinical manifestation of AD happens before the inflammatory processes is fully developed. Finally, we found a multi-protein composite approach for predicting EYO that outperformed single biomarker values. INTERPRETATION Our results suggest that the main CSF proteomic landscape changes in ADAD are due to the presence of a pathogenic mutation and occur prior to symptom onset. Improved performance of multi-protein composite to predict EYO compared to single biomarker values highlights the added value of multiplex proteomic signatures for biomarker panel development. FUNDING National Institute on Aging, Alzheimer’s Association, German Center for Neurodegenerative Diseases, Raul Carrea Institute for Neurological Research, Japan Agency for Medical Research and Development, Ministry of Health & Welfare and Ministry of Science and ICT, Republic of Korea, Spanish Institute of Health Carlos III.
Psychosocial factors influencing opioid use and refusal among breast cancer survivors: A multi-methods study
Chavez, Melody , Levin, Bruce Lubotsky, Beckstead, Jason W. , Rigg, Khary K. , Marshall, Victoria K. , Lubrano, Barbara , Chavez, Melody N , Tyson, Dinorah Martinez

Mayo Clinic

Journal of Health Psychology | March 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/13591053261434369 | PMID 41914761 Get It

Opioids are often the first-line approach to treat moderate to severe cancer-related pain. However, opioids can cause conflict and distress to cancer survivors when prescribed for pain. The objective of this multi-methods study was to explore the psychosocial factors that affect the use or refusal of opioids among breast cancer survivors. We recruited 20 breast cancer survivors treated with opioids to participate in a free-listing exercise and semi-structured interview. Results revealed that survivors felt unprepared for the intensity of pain following cancer treatments, which contributed to the use of opioids. The adverse side effects often influenced their decision to discontinue them from their pain management strategy. Finally, the addictive properties of the medication affected survivors’ use of the medication. Findings identify and recognize clinicians and researchers can promote safer, more personalized approaches to pain management to inform interventions that integrate behavioral health support and improve patient-provider communication.
Abstract B014: GPNMB:CD44 signaling drives tumor progression in translocation renal cell carcinoma
Woo, Juhyung , Feng, Kewen, Amaral, Adrianna, Palande, Vikrant , Mandal, Jayaprakash, Ray, Sangeeta, Li, H, Ged, Yasser , Singla, Nirmish, Copland, John A. , Schmidt, Laura, Linehan, W. Marston, Argani, Pedram, Lotan, Tamara, Asrani, Kaushal V. , Vidotto, Thiago , Mandal, Jayaprakash , Imada, Eddie L. , Thoburn, Christopher J. , Singla, Nirmish , Linehan, W. Marston, Argani, Pedram , Lotan, Tamara Levin

Mayo Clinic

Cancer Research | March 13, 2026 | Volume: 86 | Issue: 5_Supplement_2 | Pages: B014-B014

10.1158/1538-7445.kidney26-b014 Get It

Abstract GPNMB (Glycoprotein non-metastatic melanoma protein B) is a canonical transcriptional target of MiT/TFE proteins (TFEB/TFE3/MITF), expressed at low levels in normal tissues but upregulated in numerous MiT/TFE-driven tumors such as translocation RCC, alveolar soft part sarcoma and MITF-driven melanoma, where it is associated with poor prognosis. CDX-011 (CR011-MMAE) is an anti-GPNMB ADC, with demonstrated efficacy in pre-clinical models of TFE3-fusion RCC. To further characterize GPNMB functionality and value as a cell-surface therapeutic target in tRCC, we engineered cell lines with genomic deletion of GPNMB via CRSIPR-Cas9 editing. Deletion of GPNMB in PRCC-TFE3 cell lines [UOK120/UOK124] significantly decreased clonogenic growth in 2D, spheroid size and viability and tumor xenograft growth in NSG mice and was associated with a decrease in phosphorylation of mTORC1 substrates [p-P70S6K, p-4EBP1]. We then examined expression of CD44, the primary receptor for GPNMB, and a tumor-associated antigen associated with poor prognosis in many cancers. Expression of CD44 and its ligand SPP1/OPN, was significantly increased in bulk RNA-Seq data from multiple transgenic models of SFPQ-TFE3, PRCC-TFE3 and ASPSCR1-TFE3, in human tRCC cases compared to normal kidney, and in SFPQ-TFE3/ PRCC-TFE3 transgenic kidney tumors and an ASPSCR-TFE3 PDX model, by immunoblotting and IHC, with increased membrane localization. shRNA-mediated depletion of CD44 profoundly and specifically decreased clonogenicity of multiple TFE3-fusion lines, with no effect seen in ccRCC lines. In conclusion, GPNMB regulates the growth of tRCC cells, potentially via an autocrine mechanism involving its receptor CD44, and targeting GPNMB-CD44 signaling may be of therapeutic benefit in tRCC. Citation Format: Kaushal Asrani, Juhyung Woo, Kewen Feng, Thiago Vidotto, Adrianna Amaral, Vikrant Palande, Jayaprakash Mandal, Eddie Imada, Christopher Thoburn, Sangeeta Ray, Huili Li, Yasser Ged, Nirmish Singla, John A. Copland, Laura Schmidt, W. Marston Linehan, Pedram Argani, Tamara Lotan. GPNMB:CD44 signaling drives tumor progression in translocation renal cell carcinoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Innovations in Kidney Cancer Research: From Molecular Insights to Therapeutic Breakthroughs; 2026 Mar 13-16; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(5_Suppl_2):Abstract nr B014.
An automated plasma‐based proteotyping immunoassay for APOE ε4 zygosity classification in Alzheimer's disease
Levin, Scott , Engel, Brian, Carlson, Corey M., Hinson, Jeremiah, Holland, Mark D. , Figdore, Dan, Tiers, Laurent, Bhatt, Kinal , Schlichtmann, Ben, Hoffmann, Katie, Bae, Ye Eun, Szabo, Miklos, Um, Yoo Hyun , Algeciras-Schimnich, Alicia, Hinson, Jeremiah S. , Figdore, Daniel J. , Lim, Hyun Kook , Schlichtmann, Benjamin W. , Lehmann, Sylvain , Algeciras‐Schimnich, Alicia

Mayo Clinic

Alzheimer's & Dementia | March 8, 2026 | Volume: 22 | Issue: 3 | Pages: No page available

10.1002/alz.71143 | PMID 41789706 Get It

Abstract INTRODUCTION Determining apolipoprotein E ( APOE ) ε4 allele status, a key genetic risk factor for Alzheimer's disease (AD), requires molecular genotyping infrastructure not widely accessible beyond specialized centers. METHODS A fully automated high‐throughput apoE E4 proteotyping immunoassay was evaluated for clinical performance (460 participants across three cohorts) and analytical validity. Concordance with polymerase chain reaction (PCR)‐based genotyping and measures of analytical validity were reported. RESULTS The apoE E4 immunoassay demonstrated 99.6% (95% confidence interval [CI]: 98.4% to 99.9%) concordance with PCR‐based APOE ε4 genotype results across the pooled clinical cohort; 100.0% (95% CI: 97.1% to 100.0%) in those with AD ( N = 127) and 99.4% (95% CI: 97.8% to 99.8%) in those without AD (333). The assay met analytical validity criteria for E4 isoform specificity, interference, precision, and stability. DISCUSSION The apoE E4 immunoassay demonstrated high concordance with PCR‐based genotyping and robust analytical validity, offering an accessible alternative for APOE ε4 zygosity assessment. Highlights A novel high‐throughput plasma‐based proteotyping immunoassay for APOE ε4 zygosity classification was developed and evaluated for clinical performance and analytical validity. The apoE E4 immunoassay demonstrated high concordance (99.6%) with PCR‐based APOE ε4 genotyping across a diverse international cohort, and a robust analytical profile. An apoE E4 immunoassay may offer a more cost‐effective and accessible alternative to DNA genotyping approaches currently used for AD risk evaluation and anti‐amyloid treatment decisions.
Residual Stone Volume Predicts Health Care Consumption and Stone Events: Analysis of Two-Year Results of the ASPIRE Study
Matlaga, Brian R., Johnson, Brett, Page, Jay, Wolf, J. Stuart, Preminger, Glenn M. , Jones, Loren, Sobol, Ilya , Stern, Karen , Lipkin, Michael, Cuellar, David, Cobb, Kaitlan, Barsky, Robert, Medairos, Robert, Marguet, Charles G., Nimmagadda, Naren , Levin, Michael, Chi, Thomas, Stern, Karen L , Mueller, Thomas J. , Wolf, Jeanette, Jones, Loren, Lipkin, Michael E. , Cuellar, David, Barsky, Robert I, White, Mark, Chi, Thomas

Mayo Clinic

Journal of Endourology | February 12, 2026 | Volume: 40 | Issue: 3 | Pages: 328-334

10.1177/08927790261420565 | PMID 41674087 Get It

Purpose: The ASPiration to Improve Renal Calculi Removal Effectiveness study showed steerable ureteroscopic renal evacuation (SURE) with CVAC that significantly reduced residual stone volume at 30 days vs standard ureteroscopy (URS). This report presents 2-year health care consumption and stone events (SE) and their link to residual stone volume and other variables ( n = 101 at primary end point; n = 93 at 2 years). Materials and Methods: Logistic regression identified predictors of health care consumption events (HCEs), that is, emergency department visits, hospitalization, surgical retreatment, and SE across the study population. Incidence was compared between the treatment groups with Kaplan–Meier survival analysis. Results: At 2 years, residual stone volume was significantly associated with both HCEs and SE. For every 100 mm 3 increase in residual stone volume, the HCE risk increased by 50% to 54%, and the SE risk increased by 70%. Stone-free rate, the number of residual fragments (RFs), and RF total stone burden (based on diameter) were not predictors. Significantly fewer HCEs occurred in the SURE group (3 vs 20 events, p = 0.0004). Survival analysis confirmed this (4.3% vs 20%, log-rank p = 0.02), with a 73% risk reduction (hazard ratio 0.27, 95% Cl 0.09–0.80, p = 0.02). Fewer SE occurred in the SURE group, although not statistically significant. These subjects also had longer event-free survival. Conclusion: High-quality volumetric analysis supports evaluation of stone removal therapies, as residual stone volume predicts HCEs and SE. SURE significantly reduces the downstream incidence and risk of HCEs compared with standard URS.
Individualized Atrophy‐Based Prediction of Dementia Progression in Familial Frontotemporal Lobar Degeneration With Bayesian Linear Mixed‐Effects Modeling
Dutt, Shubir , Leichter, Dana, Wolf, Amy , Kornak, John , Clark, Annie L , Russell, Lucy L. , Bouzigues, Arabella , Cash, David M, Bocchetta, Martina , Olzinski, Molly, Ece, Bayram, Borroni, Barbara, Butler, Chris R., Clark, David, Convery, Rhian S., Darby, R. Ryan , Mendonça, Alexandre de, Dickerson, Bradford, Domoto‐Reilly, Kimiko, Ducharme, Simon, Ferry‐Bolder, Eve, Finger, Elizabeth, Foster, Phoebe H. , Galasko, Douglas R., Galimberti, Daniela, Gerhard, Alexander, Ghoshal, Nupur , Graff, Caroline, Graff‐Radford, Neill, Grant, Ian M., Hales, Chadwick M., Honig, Lawrence S., Hsiung, Ging‐Yuek, Huey, Edward D, Irwin, David John, Jiskoot, Lize C., Kremers, Walter K. , Kwan, Justin Y., Laforce, Robert, Ber, Isabelle Le, Levin, J, Litvan, Irene, Mackenzie, Ian R., Masellis, Mario, Mendez, Mario F., Moreno, Fermin, Onyike, Chiadi U. , Otto, M, Pascual, Belen, Pressman, Peter , Rademakers, Rosa, Ramos, Eliana Marisa , Ritter, Aaron, Roberson, Erik D. , Sánchez‐Valle, Raquel, Santana, Isabel, Seelaar, Harro, Snyder, Allison, Sorbi, Sandro, Synofzik, Matthis, Tartaglia, Maria Carmela, Swieten, John C. van, Vandebergh, Marijne , Vandenberghe, Rik, Heuer, Hilary W. , Miller, Bruce L., Seeley, William W., Gorno‐Tempini, Maria Luisa, Kramer, Joel H., Forsberg, Leah K., Kantarci, Kejal, Boeve, Bradley F., Boxer, Adam L. , Rohrer, J. D., Rosen, Howard J., Staffaroni, Adam M., investigators, FTD Prevention Initiative (FPI), Graff, Caroline , Galimberti, Daniela , Otto, Markus , Jiskoot, Lize C. , Moreno, Fermín , Domoto‐Reilly, Kimiko , Russell, Lucy L , Bocchetta, Martina , Bayram, Ece , Ducharme, Simon , Finger, Elizabeth C. , Galimberti, Daniela , Ghoshal, Nupur , Irwin, David J , Kwan, Justin Y , Le Ber, Isabelle , Otto, Markus , Pascual, Belen , Snyder, Allison , Synofzik, Matthis , Tartaglia, Maria Carmela , Tiraboschi, Pietro , Kantarci, Kejal , Rohrer, Jonathan D , Roberson, Erik , Kremers, Walter K , Domoto-Reilly, Kimiko , Vandebergh, Marijne , Bouzigues, Arabella , Jiskoot, Lize C , Graff, Caroline , Cobigo, Yann , Cash, David M. , Appleby, Brian S. , Borroni, Barbara , Bozoki, Andrea C , Clark, David, Convery, Rhian , Mendonça, Alexandre de , Ducharme, Simon , Ferry‐Bolder, Eve , Galasko, Douglas , Gerhard, Alexander , Graff‐Radford, Neill R. , Hales, Chadwick M. , Honig, Lawrence S. , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Kwan, Justin , Laforce, Robert , Ber, Isabelle Le , Léger, Gabriel C. , Xiong, Chengjie , Litvan, Irene , Mackenzie, Ian R. , Masellis, Mario , Mendez, Mario F. , Pascual, Belén , Rademakers, Rosa , Rowe, James B. , Sánchez‐Valle, Raquel , Santana, Isabel , Seelaar, Harro , Snyder, Allison , Sorbi, Sandro , Synofzik, Matthis , Tiraboschi, Pietro , Swieten, John C. van , Vandenberghe, Rik , Seeley, William W. , Gorno‐Tempini, Maria‐Luisa, Kramer, Joel H. , Forsberg, Leah K. , Kantarci, Kejal , Boeve, Bradley F. , Rohrer, Jonathan D. , Rosen, Howard J. , Staffaroni, Adam M.

Mayo Clinic

Annals of Neurology | January 29, 2026 | Volume: 99 | Issue: 5 | Pages: 1315-1326

10.1002/ana.78167 | PMID 41608854 Get It

Objective Age of symptom onset is highly variable in familial frontotemporal lobar degeneration (f‐FTLD). Accurate prediction of onset would inform clinical management and trial enrollment. Prior studies indicate that individualized maps of brain atrophy can predict conversion to dementia in f‐FTLD. We used a Bayesian linear mixed‐effect (BLME) prediction method for identifying accelerated brain volume loss to predict conversion to dementia. Methods Participants included 234 asymptomatic or prodromal carriers of C9orf72 , GRN , or MAPT mutations (including 21 dementia converters) with ≥3 longitudinal magnetic resonance imaging (MRI) T1‐weighted scans. The BLME models established individual voxel‐wise gray matter trajectories using the first 2 scans. Person‐specific clusters of accelerated volume loss were estimated in subsequent scans and tested as predictors of dementia conversion compared with other approaches in time‐varying Cox proportional hazard models covarying for age. Receiver‐operating characteristic (ROC) curves estimated utility of cluster volume in discriminating which participants converted to dementia within 24 months. Results The BLME cluster volume predicted conversion to dementia in f‐FTLD mutation carriers overall and separately in C9orf72 , GRN , and MAPT , with comparable hazard ratios observed for atrophy W‐maps and regional volumes. Within a 24‐month timeframe, BLME cluster volume discriminated dementia converters from non‐converters with larger areas under the curve (AUCs) than other approaches. Interpretation Bayesian‐modeled individualized atrophy scores predict dementia progression among asymptomatic f‐FTLD mutation carriers and may have increased utility compared with other structural imaging methods when studying individuals over shorter timeframes that align with clinical trial design. ANN NEUROL 20269999:n/a–n/a
Plasma levels of an N‐terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's disease
Liu, L, Ostaszewski, Beth L., Anderson, Amirah K. , Yau, Wai‐Ying Wendy , Shirzadi, Zahra , Gordon, Brian A., Hassenstab, Jason, Morris, J. Newman, Perrin, Richard J., Allegri, Ricardo F., Barthélemy, Nicolas R., Fox, Nick, Day, Gregory S., Jucker, Mathias, Levey, Allan I., Levin, Johannes, Mori, Hiroshi, Salloway, Stephen, Schofield, Peter, McDade, DO Eric, Sperling, Reisa A., Bateman, Randall J., Selkoe, Dennis J., Chhatwal, Jasmeer P., Network, and the Dominantly Inherited Alzheimer's, Xiong, Chengjie , Hassenstab, Jason , Xiong, Chengjie , Hassenstab, Jason , Schultz, Stephanie A. , Rao, Yiwen, Liu, Lei, Gordon, Brian A. , Perrin, Richard J. , Allegri, Ricardo , Barthélemy, Nicolas R. , Day, Gregory S. , Jucker, Mathias , Levey, Allan I. , Salloway, Stephen , Schofield, PR, McDade, Eric , Sperling, Reisa Anne , Bateman, Randall J. , Selkoe, Dennis J. , Chhatwal, Jasmeer P.

Mayo Clinic

Alzheimer's & Dementia | January 8, 2026 | Volume: 22 | Issue: 1 | Pages: No page available

10.1002/alz.71049 | PMID 41505233 Get It

Abstract INTRODUCTION Tau species lacking truncation of the N‐terminal region, including plasma N‐terminal tau fragment 1 (NT1), have been previously associated with cognitive decline, neurodegeneration, and tau pathology in late‐onset sporadic Alzheimer's disease (AD). METHODS Here, we examined cross‐sectional and longitudinal plasma NT1 as a possible predictor of cognitive, clinical, and core AD biomarker trajectories in autosomal dominant AD (ADAD). RESULTS NT1 levels in ADAD mutation carriers (MC; n = 132) increased across the disease continuum, compared to non‐carriers (NC; n = 75), becoming elevated about a decade prior to estimated symptom onset. Cross‐sectional and longitudinal NT1 levels in MC were associated with clinical, cognitive, and biomarker changes. NT1 increases continued in symptomatic phases of disease, a distinct trajectory from that seen with CSF p‐tau217 and other phospho‐tau species. DISCUSSION Together, our results suggest that plasma NT1—alone or combined with other tau measures—may be useful in studying AD‐related clinical, cognitive, and biomarker outcomes. Highlights Leveraging a deeply phenotyped cohort of individuals carrying a pathogenic variant for autosomal dominant Alzheimer's disease (ADAD) and their non‐carrier family members, our results suggest that plasma N‐terminal tau fragment 1 (NT1) levels mirrored changes in clinical, cognitive, and neurodegenerative measures in ADAD, particularly in late asymptomatic and early symptomatic phases of disease. NT1 levels correlated with cerebrospinal fluid (CSF) measures of tau pathology but less so with CSF or imaging measures of β‐amyloid pathology. Together with previous supportive findings in preclinical and symptomatic sporadic AD, these results suggest that plasma NT1—alone or combined with other tau measures—may be useful in studying AD‐related tau pathology and neurodegeneration across a wide spectrum of disease.